The future of Delcath Systems Inc.’s Melblez Kit for resectable ocular melanoma that is metastatic to the liver appears to depend on whether the Oncologic Drugs Advisory Committee believes improvement in hepatic progression-free survival is sufficient to demonstrate clinical benefit.
The Melblez Kit, which ODAC will review May 2, contains melphalan (GlaxoSmithKline PLC’s Alkeran) and the Delcath Hepatic Delivery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?